Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes

Scynexis, Inc.100 enrolled

Overview

This is an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age.

This is a single-arm safety study which comprises an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age who were exposed to ibrexafungerp during pregnancy, or whose conception is estimated to have occurred within four days after receiving last dose of ibrexafungerp, and are volunteering to take part in this study. Subjects will be monitored starting from exposure during pregnancy until one year after live delivery. Information on pregnancy outcomes and complications as well as fetal/neonatal/infant outcomes will be collected during the timeframe described in the protocol. Subjects can enroll in the study by calling the telephone number directly (1-888-982-7299) or through SCYNEXIS BREXAFEMME Pregnancy Study Webpage, OR her healthcare provider (HCP) can, with her consent, enroll her on her behalf. Data will be collected both retrospectively and prospectively using a variety of questionnaire that will be completed by the representative based on interview with the subject and/or HCP

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Vulvovaginal Candidiasis Candida Infection Vaginal Candidiasis

Interventions

Non-interventional studyOTHER

This is not an interventional study

Eligibility

Sex: FEMALEMin age: 0 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Exposure to ibrexafungerp during pregnancy or if conception is estimated to have occurred within 4 days of the last dose of ibrexafungerp 2. Subject and/or parent/legal representative consents to participate and agrees to the conditions and requirements of the study including the interview schedule/completion of questionnaire and release of medical records * Subject can be identified by the sponsor or HCP, in terms of confirmed pregnancy. A self-reported pregnancy will be considered as confirmed pregnancy if the Urine Pregnancy Test (UPT) result is positive. * A woman can self-enroll in the study or her healthcare provider (HCP), with her consent, can enroll her on her behalf. Exclusion Criteria: 1. Females who were not exposed to safety study medications during pregnancy 2. Refusal to participate in the study 3. An inability to provide an accurate medical history or give informed consent

Locations (1)

AWINSA

New Delhi, Vasant Vihar, India

RECRUITING

Outcomes

Primary Outcomes

Major Structural Defects

To collect and describe selected fetal/neonatal/infant outcomes (i.e., major and minor congenital malformations, small for gestational age, and postnatal growth and development) at birth and through up to the first year of life of infants born to women exposed to ibrexafungerp during the defined pregnancy exposure window

Time frame: From Brexafemme exposure up to one year after birth

Secondary Outcomes

To collect and describe pregnancy outcomes

Live birth, spontaneous abortions, stillbirths, elective abortions, and preterm births

Time frame: From Brexafemme exposure up to one year post birth

Central Contacts

Sanjeev Miglani, MD

CONTACT

+91-9910533655 sanjeev.miglani@awinsals.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.